Phase 2 Study of SR-8541A in Combination with Botensilimab and Balstilimab in Subjects with Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
Latest Information Update: 31 Dec 2024
Price :
$35 *
At a glance
- Drugs SR 8541A (Primary) ; Balstilimab; Botensilimab
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Stingray Therapeutics
- 27 Dec 2024 Status changed from not yet recruiting to recruiting.
- 27 Sep 2024 New trial record